The global dry eye syndrome treatment market is estimated to increase at a significant rate over the forecast period. Increasing in the geriatric population is the major factor governing the market. According to the survey by Shire plc., it was observed that women above 50 years are more likely to be affected by dry eye disease. In addition, increasing awareness about the diagnosis and treatment of the disease, an increase in the use of contact lenses, and the rise in healthcare expenditure levels are estimated to boost the market.
Increasing prevalence of eye disorders especially dry eye disease among the population is expected to grow the market. In 2015, the National Eye C.A.R.E (Current Attitudes Related to Eye Health) conducted an online survey under Shire plc. which includes around 1,000 eye care professionals. This survey resulted that around 1,200 adults had dry eye symptoms.
The multi-screen modern lifestyle which includes eye strain due to more usage of the tablet, mobile, and computer screens are responsible for triggering the eye-related problems. According to the survey announced by Shire plc., around 9 in 10 eye care professionals believe that the above-mentioned reasons are the major factors driving dry eye syndrome market over the forecast period.
Common risk factors associated with this syndrome are sex, age, environmental conditions, and autoimmune disorders with systemic medications. The presence of a wide range of treatment options available such as lubricant eye drops, punctual bags, artificial tears, and drugs for dry eye syndrome is expected to add fuel to the market.
However, the dearth of skilled ophthalmologists restrains the growth of the market. Since the symptoms of dry eye disease are common as other eye-related diseases at the initial stage such as itchy eyes, burning sensation, heavy eyes, red eyes, sore eyes, and blurred vision. This creates a delay in detecting of dry eye disease.
Based on the type, dry eye syndrome treatment market is divided into evaporative dry eye syndrome and aqueous dry eye syndrome. According to the survey published in the ARVO journal, evaporative dry eye syndrome is more common as compared to aqueous dry eye syndrome. On the basis of the treatment, the market is segmented into cyclosporine, corticosteroids, artificial tears, and punctual bags. According to the NCBI, among dry eye patients over 65 years of age, 25% apply artificial tears and 75% of them visited eye care professionals before starting any medications. Moreover, on the basis of distribution channels, the market is segmented as online pharmacies, hospital pharmacies, and retail pharmacies.
According to the region, the dry eye syndrome treatment market is segmented into North America, Europe, Latin America, Asia-Pacific, and Middle East Asia. North America is estimated to hold the largest market share owing to the presence of key market players associated with the dry eye syndrome treatments and huge patient population. In 2017, based on the America Journal of Ophthalmology, more than 16 million U.S. adults are diagnosed with dry eye disease. Moreover, the presence of developed economies within the region is adding fuel to its growth in this region.
Major participants include Novartis AG (Alcon), ALLERGAN, Johnson & Johnson Vision Care, Inc., Otsuka Pharmaceutical Vo. Ltd., Shire, OASIS Medical, Santen Pharmaceutical Co. Ltd., AFT Pharmaceuticals, I-Med Pharma Inc., Novaliq GmbH, Sentiss Pharma Pvt. Ltd., and Scope Ophthalmics Ltd.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.